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Abstract
Background: Mayaro virus is endemic in South America and sporadic outbreaks have been described. It causes a
dengue-like febrile illness accompanied by severe and long-lasting polyarthralgias. Outside endemic regions, however,
the disease is not well known and can be misdiagnosed as dengue. International travellers are at risk to acquire Mayaro
virus and due to increased worldwide travel infectious disease specialists need to be aware of such rare clinical entities.
Case presentation: We report the first Mayaro virus infection imported into Germany. A 20-year-old woman
developed fever, myalgia, maculopapular rash, and polyarthralgias following a 10-day trip in the Rurrenabaque region
of Bolivia. Severe polyarthralgias persisted for 5 months and were treated with non-steroidal anti-inflammatory drugs.
Serological analysis demonstrated Mayaro virus-specific-IgM and -IgG antibodies two months after onset of symptoms.
Except for CXCL8/IL-8 other proinflammatory chemokines and cytokines were unremarkable at this time.
Conclusions: Dissemination of knowledge on rare disease might improve patient management. Understanding the
inherent features of Mayaro virus infection and how the virus interacts with its host are essential for optimal patient
care and therapy.
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Background
Mosquito-borne alphaviruses belong to the family
Togaviridae and have a worldwide distribution. They
can be associated with rheumatic disease in humans.
The most important arthritogenic alphaviruses are
Barmah Forest virus (BFV), chikungunya virus (CHIKV),
Ross River virus (RRV), Sindbis virus (SINV), and Mayaro
virus (MAYV). Occasionally, these arthritogenic alpha-
viruses can cause large and unpredictable outbreaks as
seen in the 2004–2011 CHIKV epidemic in the Indian
Ocean [1]. Geographic range expansion of alphaviruses
and increased worldwide travel are of emerging public
health concern [2,3]. Of note, importation of alphaviruses
into non-endemic regions can delay proper treatment as
doctors are not familiar with the diseases and reliable
diagnostic methods are lacking at large [3,4]. Disease in
humans is usually self-limiting, but polyarthralgia can be
debilitating and long-lasting. This prominent feature has
been reported in particular in cases of CHIKV and MAYV
infection. However, little is known about the underlying
mechanism of polyarthralgia. It has been postulated that
the inflammatory immune response can contribute to the
pathology [5]. Here, we describe the first MAYV case
imported into Germany and present data on the inflam-
matory immune response during the polyarthralgic stages
of the disease.
Case presentation
In July 2012, a 20-year old woman presented to our out-
patient clinic with symmetrical polyarthritis after a long-
term travel to South America. At presentation, she
complained about highly painful ankles and elbows, and
she was barely able to walk without assistance. Between
September 2011 and June 2012 she had travelled as a
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tourist through Peru, Bolivia, and Ecuador. In Mid-April
2012 she spent 10 days in the tropical rainforest of the
Rurrenabaque region, which is situated in the Amazon
basin about 400 km north of La Paz, Bolivia. There, she
volunteered in a wildlife resort, taking care of a variety
of monkeys and wild cats. One day after leaving the re-
sort she developed spiking fevers, headache, myalgia
followed by aphthous oral ulcers and a maculopapular
rash of the whole body four days later. Around the same
time she developed a diffuse arthralgia, which after ini-
tial improvement slowly worsened and became highly
incapacitating. Her previous medical history was unre-
markable. She did not take regular medication. Prior to
her travel, she had received complete vaccinations for
yellow fever, rabies, hepatitis A and B.
On physical examination tenderness and mild swelling
of both ankles was noted. Tenderness of the elbows,
shoulders and interphalangeal joints and wrists without
swelling was also observed.
Results of a full blood count, liver and renal function
tests were normal, as were levels of electrolytes, lactate de-
hydrogenase, and C-reactive protein. Blood cultures
remained sterile. Blood smears for malaria were repeatedly
negative. Serologic testing for cytomegalovirus, hepatitis C
virus, human immunodeficiency virus, Borrelia burgdorferi,
and Treponema pallidum were negative. Serology for Ep-
stein-Barr virus and parvovirus B19 was indicative of past
infection. A slightly raised dengue virus (DENV) IgG
was interpreted as cross-reactivity after yellow fever
vaccination while DENV IgM was negative. In addition,
autoimmune serology including anti-citrullin peptide anti-
bodies or anti-nuclear antibodies was negative.
Due to her travel to the Amazon basin and prolonged
course of arthralgia, MAYV infection was considered as
a differential diagnosis. Serologic testing for mosquito-
borne alphaviruses using the indirect immunofluores-
cence test (IIFT) and virus neutralization test (VNT)
confirmed the diagnosis of MAYV infection (Table 1).
Testing for MAYV RNA was not performed, since the
time of presentation was more than 2 months after dis-
ease manifestation.
Serum samples collected 83, 106, and 167 days after
onset of symptoms, respectively, were analyzed for che-
mokine/cytokine levels using the Cytometric Bead Array
(CBA) Human Chemokine Kit and Human Th1/Th2
Cytokine kit (Becton Dickenson, Heidelberg, Germany)
according to the manufacturer’s instructions.
Except for CXCL8/IL-8, which was elevated more than
15-fold on day 83 after onset of symptoms, chemo-
kines (CCL5/RANTES, CXCL9/MIG, CCL2/MCP-1, and
CXCL10/IP-10) and cytokines (IL-2, IL-4, IL-5, IL-10,
TNF-α, and IFN-γ) were not different to healthy controls
(n = 5 samples) (Table 2).
The patient was treated symptomatically with non-ster-
oidal anti-inflammatory drugs (NSAID). During follow up
visits the patient reported persistent arthalgias of both an-
kles and elbows, which slowly improved over time. The
patient continued to take NSAID for over 2 months and
her symptoms finally resolved after 5 months.
Discussion
To our knowledge, this MAYV case is the fourth of a
European patient with a travel history to South America
and in particular the first imported MAYV case into
Germany [4,6,7]. MAYV infection is still rare in travel-
lers and consultation of infectious disease specialists is
instrumental in making the correct diagnosis [4].
Our patient presented with a travel and exposure history
typical for an infection with an arthritogenic alphavirus
and displayed symptoms identical to reports published
Table 1 Serological testing for alphaviruses
Indirect immunofluorescence assay Virus neutralization assay
First serum sample* Second serum sample** First serum sample* Second serum sample**
Virus IgM IgG IgM IgG
Mayaro virus (MAYV) 1:10240 1:160 1:20480 1:160 1:80 1:160
Semliki forest virus (SFV) 1:20 < 1:20 1:40 < 1:20 1:40 1:40
O’nyong-nyong (ONNV) 1:20 < 1:20 1:40 < 1:20 < 1:20 < 1:20
Chikungunya virus (CHIKV) 1:20 < 1:20 1:40 < 1:20 < 1:20 < 1:20
Ross river virus(RRV) 1:20 < 1:20 1:20 < 1:20 < 1:20 < 1:20
Barmah forest virus (BHV) 1:20 < 1:20 1:20 < 1:20 < 1:20 < 1:20
Sindbis virus (SINV) 1:20 < 1:20 1:20 < 1:20 < 1:20 < 1:20
Western equine encephalitis virus (WEEV) 1:20 < 1:20 1:20 < 1:20 < 1:20 < 1:20
Eastern equine encephalitis virus(EEEV) 1:20 < 1:20 1:20 < 1:20 < 1:20 < 1:20
Venezuelan equine encephalitis virus (VEEV) 1:20 < 1:20 1:20 < 1:20 < 1:20 < 1:20
*Serum sample day 83 after onset of symptoms.
**Serum sample day 106 after onset of symptoms.
Antibody titers were measured by indirect immunofluorescence test and virus neutralization test. Shown are results on day 83 and 106 after onset of symptoms, respectively.
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previously [4,6,7]. However, knowledge about exotic
alphaviruses is rather limited among general practitioners
and MAYV infection might frequently be misdiagnosed as
dengue on clinical grounds. In our case serologic results
rapidly confirmed the clinical diagnosis supporting the im-
portance of specific laboratory tests. It should be noted,
however, that diagnostic tests for exotic alphaviruses are
not widely available hampering the diagnosis in routine
practice.
VNT is considered gold standard for the diagnosis of
MAYV infection. However, the requirement for a biosafety
level 3 laboratory to conduct these assays considerably
limits their utility. IIFT and ELISA have been also de-
scribed, but they are prone to cross-reactivity between
alphaviruses [4,6]. Diagnosis in our case was unambiguous
and no significant cross-reaction with related alphaviruses
was observed. Interestingly, MAYV IgM antibodies were
detectable for at least 3,5 months. It remains speculative if
persisting IgM can serve as a diagnostic indicator of severe
disease and arthritis [8,9].
Beyond pure case detection it should be noted that
travellers can potentially act as sentinel for emerging in-
fectious diseases [10]. In light of the spread of compe-
tent vectors for mosquito-borne diseases in Europe and
elsewhere, surveillance of vector-borne diseases is of
major public health importance. Therefore, the dissem-
ination of reliable diagnostic methods is an important
prerequisite both for individual and public health as ex-
perienced with other emerging infections, e.g. CHIKV
and west nile virus [3,11].
Among the arthritogenic alphaviruses MAYV is
restricted to South America and infections have
been reported from countries including Brazil, Bolivia,
Colombia, the Guiana’s, and Venezuela. Sporadic outbreaks
involving up to 100 cases have been described in several re-
gions [12-14]. Resident forrest workers and hunters are at
highest risk to acquire MAYV infection [4,6,7]. In South
America, MAYV is responsible for about 1% of arbovirus-
associated febrile illness [15]. The virus is transmitted by
bites of Haemagogus janthinomys which lives in the forest
canopy and propagates in a sylvatic cycle predominantly in
monkeys [16,17]. Hence, working and living in the Amazon
rain forest is the most important risk factor for the acquisi-
tion of MAYV infection [12,13,18]. Clearly, our patient was
at risk while working in a wildlife resort. Recently, however,
also cases of urban transmission of MAYV infection have
been described [19].
From a clinical perspective arthritogenic alphaviruses
cause a similar picture consisting of acute fever, malaise,
headache, maculo-papular rash, myalgia lasting for
3 – 7 days, and a characteristic and often debilitating
polyarthraglia/polyarthritis lasting up to 6 months [20]. A
rash is found in 20 – 60% of patients [14,19,21] In a clas-
sical fashion our patient reportedly suffered from these
cardinal symptoms during the acute phase of infection.
Viraemia is short-lived and controlled by the innate im-
mune system as well as the appearance of antibodies after
5–7 days. The hallmark of all arthritogenic alphaviruses
are sometimes long-lasting polyarthralgias and/or polyar-
thritis. There is evidence that virus induced inflammation
is responsible for these arthropathies [20]. To the best of
our knowledge no reports on the inflammatory cytokine
response in MAYV infection are available to date. Suppor-
ting the findings of Chow et al., who analyzed patients
with persistent arthralgia induced by CHIKV infection, the
Th1/Th2 response remained below the limit of detection
at all time points in our patient. A slightly elevated IL-8
concentration could be interpreted as waning levels after
acute infection [5]. Interestingly, Chow et al. could show
that levels of IL-6 and granulocyte macrophage colony-
stimulating factor were associated with persistent arthral-
gias. Further studies on MAYV are needed, as both
markers were not included in our panel. Although TNF-α
and INF-γ are involved in chronic inflammatory diseases
such as rheumatic arthritis and were detected in a number
of arthritogenic alphavirus infections we did not detect in-
creased levels in our patient. Differences in genetic back-
ground, disease severity or the etiologic agent may
account for this finding and require further studies. Be-
yond the analysis of cytokines/chemokines in serum the
analysis of gene expression profiles of these immune me-
diators may shed more light on the immune response in
MAYV infection.
Conclusions
Here, we report the first case of MAYV associated arth-
ritis in a returning traveller from Germany. No inflam-
matory correlate was detectable despite long term
Table 2 Analysis of cytokine/chemokine levels









CXCL8/IL-8 45,9 4,1 2,7 2,9
CCL5/RANTES 10277 10218 6958 10005
CXCL9/MIG 46 31,6 20,1 22,8
CCL2/MCP-1 70,1 80,9 85,6 66,1
CXCL10/IP-10 129,6 77,2 61,4 43,3
IL-2 0 0,1 0,9 0,01
IL-4 0 0 0 0
IL-5 0,2 0,3 0,5 0,1
IL10 0,8 0,5 0,9 0,8
TNF-α 0 0 0 0
IFN-γ 0 0,5 0 0
Cytokine and chemokine response as measured on three consecutive dates
within the chronic stage of MAYV disease. The control represents the mean of
5 individual determinations of 5 healthy volunteers.
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sequelae. With increasing intercontinental travel, infec-
tious disease specialists and rheumatologists need to be
aware of alphavirus infection as a cause of febrile illness
followed by persisting polyathralgia. Our clinical case il-
lustrates that MAYV infection should be considered
after travel to tropical South America, especially, if the
travel itinerary included extended exposure in the Amazon
rain forest and its wildlife.
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